Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase

Completed

Conditions studied: Bacteremia, AmpC Beta-lactamase

In brief

Nosocomial bloodstream infections are important causes of morbidity and mortality caused by AmpC beta-lactamase-producing Enterobacteriaceae. The information collected will optimize the management of patients with nosocomial bloodstream infections.

Key facts

Study ID

NCT00414193

Run by

University of Pittsburgh

People needed

1000

Starts

2007-02-01

Expected to finish

2017-12-01

Last updated by the study team

2018-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical information is collected by chart review of "case" and "control" patients. A "case" patient is defined as follows:
• One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii.
• The patient received piperacillin/tazobactam as the initial empiric therapy.
• The organism was susceptible to piperacillin/tazobactam.
• A "control" patient is defined as follows:
• One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii.
• The patient received a carbapenem or fluoroquinolone antimicrobial as the initial empiric therapy.
• The organism was susceptible to the empiric regimen.

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.